CinDome Pharma, a CinRx portfolio company, secured a $40 million Series B financing extension from Perceptive Advisors & CinRx Pharma. This funding will support the ongoing development of deudomperidone (CIN-102) for chronic #gastroparesis . More here: bit.ly/3V2Ltqc

Check out the new website for CinRx portfolio company, CinDome Pharma, which is focused solely on deudomperidone, a potentially safe, chronic therapy for #gastroparesis . Visit to learn more about our approach: cindome.com

CinFina Pharma, a CinRx portfolio company, announced FDA clearance of its CIN-110 Investigational New Drug Application (IND) for the treatment of #obesity & the first participant dosed in its Phase 1 trial for this exciting potential therapy. Learn more: bit.ly/4akyyoi

$VTVT we will find out why G42 and CinRx chose to strike deals with Vtv at 2.41$ per share.

Introducing the new website for CinRx portfolio company CinFina Pharma! This site highlights CinFina’s pipeline of high-impact monotherapy and combination treatments for people with #obesity . Check it out to learn more: cinfina.com

Tune in to hear Gavin Samuels, CBO at CinRx, discuss his #lifesciences career journey that led him to CinRx and his perspectives on #dealmaking strategies on the #businessofbiotech podcast with host Matt Pillar. Check out the episode: bit.ly/3TEC8E5

#ICYMI , Dr. Jon Isaacsohn, CEO at CinRx, discusses how our unique hub & spoke model allows us to accelerate the development of much-needed medicines for patients through our portfolio companies with host Daniel S. Levine on the BioReport podcast. Listen here: bit.ly/49T3ZpZ

$VTVT CinRx Pharma now listed as a developer for TTP399 and on their pipeline page it says phase 3.

Getting close…

#biotech #EASD2023 #jdrf

#IBSD is a complex & highly prevalent condition that significantly impacts patients’ quality of life & mental health. Mary Bond, CTSO at CinRx, shares the promise of providing a safe, effective & long-term treatment for patients. #IBSAwarenessMonth

~5% of U.S. adults suffer from #IBSD . In recognition of #IBSAwarenessMonth we continue raising awareness of the need for better therapeutic options for IBS-D that are safe, effective & convenient to effectively manage this chronic & debilitating condition. cinrx.com/portfolio/#cin…

ก้ายง่าว

Despite recent #obesity treatment breakthroughs, a need remains for new targets and approaches. CinRx portfolio company CinFina is on a mission to fill this. In honor of #WorldObesityDay , read more from CinRx CEO Dr. Jon Isaacsohn in this article: tinyurl.com/pckjv3mu #WOD24

#ICYMI , CinRx CEO Dr. Jonathan Isaacsohn’s recent STAT First Opinion Piece discusses the #obesity landscape & the need for drug developers to prioritize preservation of lean muscle mass & energy expenditure in #weightloss treatments. bit.ly/44bzZmY

🚀 New Venture Deal! 🚀

🏢 Company: CinDome Pharma
📜 Summary: CinDome Pharma, a CinRx portfolio company dedicated to advancing a safe, chronic therapy for gastroparesis, raised a $40M Series B from Perceptive Advisors and CinRx Pharma
🔗 Link: businesswire.com/news/home/2024…

Concurrent with the initiation of our Ph2 study of CIN-103 for the treatment of chronic #IBSD , Dr. Darren Brenner, Prof. of #Gastroenterology at NU Wildcats Football shared his thoughts on its potential to address the unmet need for a long-term treatment. bit.ly/48ug4QW

readawrite.com/a/e9cd0ff4e9bf…

CinPhloro Pharma, part of CinRx Portfolio, began Phase 2 enviva Study of CIN-103 for IBS-D, with first participant dosed.

More Info: pryzm.ozmosi.com/product/31868 $XBI $IBB $XPH $PPH

Thanks, Gavin Samuels, CBO of CinRx for the chat at #BIO2023 #biotech

CinRx's CinDome Pharma to showcase Deudomperidone (CIN-102) in a poster presentation at 2023 Digestive Disease Week® Conference.

More Info: pryzm.ozmosi.com/product/22638 $XBI $IBB $XPH $PPH

CinRx Pharma kicks off Phase 2 study for Deudomperidone (CIN-102) in treating Diabetic Gastroparesis, with first participant dosed

More Info: pryzm.ozmosi.com/product/22638 $XBI $IBB $XPH $PPH